

## LIST OF PUBLICATIONS

### A. Original Articles: (Peer Review)

		*IF	**Ranking
1.	P. Jolliet, C. Magnin, <b>J-F. Dufour</b> , PF. Unger. Approche de l'embolie pulmonaire massive avec état de choc. Journal européen des urgences. 1990;4:245-248.	-	
2.	<b>J-F. Dufour</b> , F. Waldvogel. Les méningites de l'adulte à Genève. Revue de 257 cas. Schweiz. Wochenschrift. 1991; Supplementum 35:1-37.	0.283	
3.	<b>J-F. Dufour</b> , C. Stoupis, F. Lazeyras, P. Vock, F. Terrier, J. Reichen. Alterations in hepatic fructose metabolism in cirrhotic patients demonstrated by dynamic P-31 spectroscopy. Hepatology 1992;15:835-842.	4.073	
4.	<b>J-F. Dufour</b> , J. Reichen. Hepatic accumulation of lysosomes with defective transcytotic vesicular pathways in cirrhotic rat liver. Hepatology 1992;16:997-1006.	4.073	
5.	F. Shulman, R. Montali, M. Bush, S. Citino, L. Tell, J. Ballou, T. Hudson, M. St-Pierre, <b>J-F. Dufour</b> , Z. Gatmaitan, I. Arias, F. Johnson. Dubin-Johnson-like syndrome in Golden Lion Tamarins ( <i>Leontopithecus rosalia rosalia</i> ). Vet. Pathol. 1993;30:491-498.	0.682	
6.	<b>J-F. Dufour</b> , A. Zimmermann, J. Reichen. Increased hepatic lysosomal activity in biliary cirrhosis originates from hepatocytes rather than from macrophages. J. Hepatol. 1994;20:524-530.	3.154	
7.	<b>J-F. Dufour</b> , T. Turner, I. Arias. Nitric oxide blocks canalicular contraction by inhibiting InsP <sub>3</sub> -dependent Ca <sup>2+</sup> mobilization. Gastroenterology 1995;108:841-849.	8.203	
8.	M. St.-Pierre, <b>J-F. Dufour</b> , I. Arias. Stimulation of bile acid independent bile flow with bromo-cyclic guanosine monophosphate. Hepatology. 1996;24:1487-1491.	6.040	
9.	<b>J-F. Dufour</b> , Karim A. Fawaz, E. Libby. Botulinum toxin injection for secondary achalasia with esophageal varices. Gastr. Endosc. 1997;45:191-193.	2.770	
10.	<b>J-F. Dufour</b> , MM. Kaplan. Methotrexate and acute liver toxicity. Letter. N. Engl. J. Med. 1996;335:898.	24.834	
11.	M. St.-Pierre, <b>J-F. Dufour</b> , I. Arias. Disruption of actin organization by Cytochalasin D does not impair biliary secretion of organic anions. Hepatology 1997;25:970-975.	5.849	
12.	<b>J-F. Dufour</b> , I. Arias and T. Turner. IP <sub>3</sub> and Ca <sup>2+</sup> regulate the Ca <sup>2+</sup> channel function of the hepatic IP <sub>3</sub> receptor. J. Biol. Chem. 1997;272:2675-2681.	6.963	
13.	<b>J-F. Dufour</b> , R. DeLellis, MM. Kaplan. Reversibility of hepatic fibrosis in autoimmune hepatitis? Ann Int Med. 1997;127:981-984.	12.047	
14.	M. St.-Pierre, T. Schlenker, <b>J-F. Dufour</b> , D. Jefferson, J.G. Fitz, I. Arias. Stimulation of cGMP production by natriuretic peptide and effect on Cl <sup>-</sup> permeability in human biliary cells. Gastroenterology. 1998;114:782-790.	10.330	

15.	<b>J-F. Dufour</b> , R. DeLellis, MM. Kaplan. Regression of hepatic fibrosis in hepatitis C with long term interferon alpha therapy. <i>Dig Dis Sci.</i> 1998;43:2573-6.	1.972	
16.	C. Seiler, <b>J-F. Dufour</b> , E. Renner, M. Schilling, M. Büchler, P. Bischoff, J. Reichen. Primary liver disease as a determinant for acute rejection after liver transplantation. <i>Langenbeck's Arch Surg</i> 1999;384:259-263.	1.175	
17.	<b>J-F. Dufour</b> , M. Lüthi, M. Forestier, F. Magnino. Expression of inositol 1,4,5-trisphosphate receptors isoforms in rat biliary cirrhosis. <i>Hepatology.</i> 1999;30:1018-26.	7.334	
18.	F. Magnino, M. St-Pierre, M. Lüthi, M. Hilly, J-P. Mauger, <b>J-F. Dufour</b> . Expression of hepatic intracellular calcium channels and pumps after partial hepatectomy in rat. <i>Mol Cell Biol Res Com.</i> 2000;3:374-9.	-	
19.	L. Mery, F. Magnino, K. Schmidt, K.H. Krause, <b>J-F. Dufour</b> . Alternative splice variants of hTrp4 differentially interact with the C-terminal of the inositol 1,4,5-trisphosphate receptors. <i>FEBS Letters.</i> 2001;487:377-83.	3.644	
20.	C. Redaelli, M. Wagner, Y-H. Tien, L. Mazzucchelli, P. Stahel, M. Schilling, <b>J-F. Dufour</b> . $1\alpha$ , 25 dihydroxychole-calciferol reduces rejection and improves survival in rat liver allografts. <i>Hepatology.</i> 2001;34:926-34.	8.096	
21.	<b>J-F. Dufour</b> , D. Pratt. Alagille syndrome with colonic polyposis. <i>Am J Gastroenterology.</i> 2001;96:2775-7.	3.549	
22.	C. Redaelli, M. Wagner, L. Krahenbuhl, B. Gloor, M. Schilling, <b>J-F. Dufour</b> , M. Büchler. Liver Surgery in the Era of Tissue-preserving Resections: Early and Late Outcome in Patients with Primary and Secondary Hepatic Tumors. <i>World J Surg.</i> 2002;26:1126-32.	1.644	
23.	C. Redaelli, <b>J-F. Dufour</b> , M. Wagner, M. Schilling, M. Hüsler, L. Krähenbühl, M. Büchler, J. Reichen. Preoperative Galactose Elimination Capacity predicts morbidity and survival after hepatic resection. <i>Ann of Surgery</i> 2002;235:77-85.	6.674	
24.	F. Magnino, K. Schmidt, L. Mery, <b>J-F. Dufour</b> . Rat inositol 1,4,5-trisphosphate receptor isoform 2 interacts with itself in its C-terminal portion and upstream of the first transmembrane domain. <i>Eur J Biochem.</i> 2001;268:5981-8.	2.849	
25.	J. Sneyd, <b>J-F. Dufour</b> . A dynamic model for the inositol tri-phosphate receptor. <i>Proc. Natl. Acad. Sci USA.</i> 2002;99:2398-403.	10.700	
26.	B. Helbling, I. Stamenic, F. Viani, J-J. Gonvers, <b>J-F. Dufour</b> , J. Reichen, G. Cathomas, M. Steuerwald, J. Borovicka, M. Sagmeister, E. Renner. Interferon and Amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial. <i>Hepatology.</i> 2002;35:447-54.	9.825	
27.	C. Redaelli, Y-H. Tian, T. Schaffner, M. Ledermann, H. Baer, <b>J-F. Dufour</b> . Extended preservation of rat liver graft by induction of heme oxygenase-1. <i>Hepatology.</i> 2002;35:1082-92.	9.825	

28.	H-P. Bode, L. Wang, D. Cassio, M. F. Leite, M. St-Pierre, K. Hirata, K. Okaszki, M. Sears, P. Meda, M. Nathanson, <b>J-F. Dufour</b> . Expression and regulation of gap junctions in rat cholangiocytes. <i>Hepatology</i> . 2002;36:631-49.	9.825	
29.	K. Hirata, <b>J-F. Dufour</b> , K. Shibao, R. Knickelbein, A. O'Neill, H-P. Bode, D. Cassio, M. St-Pierre, N. LaRusso, M. F. Leite, M. Nathanson. Regulation of Ca <sup>2+</sup> signaling in rat bile duct epithelia by IP <sub>3</sub> receptor isoforms. <i>Hepatology</i> . 2002;36:284-96.	9.825	
30.	L. Mery, B. Strauss, <b>J-F. Dufour</b> , K. H. Krause, M. Hoth. The subcellular localization of the cation channel hTRP4 depends on its interaction with EBP50 and the actin-binding proteins of the ERM family in HEK293 cells. <i>J Cell Sci</i> . 2002;115:3497-3508.	6.954	
31.	<b>J-F. Dufour</b> , M. Zimmermann, J. Reichen. Severe autoimmune hepatitis in patients with previous spontaneous recovery of a flare. <i>J Hepatol</i> . 2002;37:748-52.	4.974	
32.	H-P. Dinkel, K. Wittchen, H. Hoppe, <b>J-F. Dufour</b> , A. Zimmermann, J. Triller. Transjugular liver core biopsy: indications, results, and complications. <i>Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr</i> . 2003;175:1112-9.	1.786	0.602
33.	A. Krauskopf, P. Lhote, M. Mutter, <b>J-F. Dufour</b> , U. Ruegg, T. Buetler. Vasopressin type 1A receptor upregulation by cyclosporin A in vascular smooth muscle cells is mediated by superoxide. <i>J Biol Chem</i> . 2003;278:41685-90.	6.482	0.885
34.	J. Hovinga, M. Solenthaler, <b>J-F. Dufour</b> . Congenital dyserythropoietic anemia type II (HEMPAS) and hemochromatosis: a report of 2 cases. <i>Eur J Gastroenterol Hepatol</i> . 2003;15:1141-7.	1.578	0.489
35.	<b>J-F. Dufour</b> , H-P. Dinkel, A. Zimmermann. Image of the month. <i>Gastroenterology</i> . 2003;125:1010.	12.718	1.000
36.	Y. Vashist, D. Semela, <b>J-F. Dufour</b> . Hyperdynamic circulation in liver cirrhosis: desensitization of vasoconstrictive receptors by G protein-coupled receptor kinases. <i>Med Hypothesis</i> . 2004;62:82-85.	0.607	0.155
37.	C. Redaelli, D. Semela, F. Carrick, M. Ledermann, D. Candinas, B. Sauter, <b>J-F. Dufour</b> . Effect of vascular endothelial growth factor on functional recovery after hepatectomy in lean and obese mice. <i>J Hepatol</i> 2004;40:305-312.	4.816	0.935
38.	J. Sneyd, M. Falcke, <b>J-F. Dufour</b> , C. Fox. A comparison of three models of the inositol trisphosphate receptor. <i>Prog Biophys Mol Biol</i> . 2004;85:121-40.	4.551	0.875
39.	A. De Gottardi, F. Touri, C. Maurer, A. Perez, O. Maurhofer, G. Ventre, C. Bentzen, E. Niesor, <b>J-F. Dufour</b> . The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer. <i>Dig Dis Sci</i> . 2004;49:982-9.	1.427	0.370
40.	M. St-Pierre, T. Stallmach, A. Freimoser, A. Grunschober, <b>J-F. Dufour</b> , M. Serrano, J. Marin, Y. Sugiyama, P. Meier. Temporal expression profiles of organic anion transport proteins in placenta and fetal liver of the rat. <i>Am J Physiol Regul Integr Comp Physiol</i> . 2004;287:R1505-16.	3.405	0.808

41.	O. Guenat, <b>J-F. Dufour</b> , P.D. van der Wal, W.E. Morf, N.F. de Rooij, M. Koudelka-Hep. Microfabrication and characterization of an ion-selective microelectrode array platform. <i>Sensors and Actuators B:Chemical</i> 2005;105:65-73.	2.646	0.814
42.	A. Muzzi, G. Leandro, L. Rubbia-Brandt, R. James, O. Keiser, R. Malinverni, <b>J-F. Dufour</b> , B. Helbling, A. Hadengue, J-J. Gonvers, B. Mullhaupt, A. Cerny, M. Mondelli, F. Negro. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patient. <i>J hepatol</i> 2005;42:41-6.	4.931	0.913
43.	H. Chtioui, A. Zimmermann, <b>J-F. Dufour</b> . Unusual evolution of posterior reversible encephalopathy syndrome (PRES) one year after liver transplantation. <i>Liver Transplantation</i> . 2005;11:588-90.	4.447	0.986
44.	L. Wang, A-C. Pigué, K. Schmidt, T. Tordjmann, <b>J-F. Dufour</b> . Activation of CREB by tauroursodeoxycholic acid protects cholangiocytes from apoptosis induced by mTOR inhibition. <i>Hepatology</i> . 2005;41:1241-51.	9.792	0.978
45.	J. Martin, F. Magnino, K. Schmidt, A-C. Pigué, J-S. Lee, D. Semela, M. V. St-Pierre, A. Ziemiecki, D. Cassio, C. Brenner, S. Thorgeirsson, <b>J-F. Dufour</b> . Hint2, a mitochondrial apoptotic sensitizer down-regulated in hepatocellular carcinoma. <i>Gastroenterology</i> . 2006;130:2179-88.	12.457	1.000
46.	<b>J-F. Dufour</b> , C. Oneta, J-J. Gonvers, F. Bihl, A. Cerny, J-M. Cereda, J-F. Zala, B. Helbling, M. Steuerwald, A. Zimmermann and the SASL. Randomized placebo-controlled trial testing ursodeoxycholic acid and vitamin E in non-alcoholic steatohepatitis. <i>Clin Gastro Hep</i> 2006;4:1537-1543.	0.91892	0.919
47.	D. Semela, A-C. Pigué, M. Kolev, K. Schmitter, R. Hlushchuk, V. Djonov, C. Stoupis, <b>J-F. Dufour</b> . Vascular remodelling and anti-tumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. <i>J Hepatol</i> 2007;46:840-8.	6.642	0.94
48.	Y. Banz, D. Inderbitzin, CA. Seiler, SW: Schmid, <b>J-F. Dufour</b> , A. Zimmermann, P. Mohacsi, D. Candinas. Bridging hyperacute liver failure by ABO-incompatible auxiliary partial orthotopic liver transplantation. <i>Transplant Int</i> . 2007;20:722-7.	2.300	0.799
49.	H. Chtioui, D. Semela, M. Ledermann, A. Zimmermann, <b>J-F. Dufour</b> . Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis. <i>Liver Int</i> . 2007;27:764-71.	2.559	0.62
50.	J. Plock, S. Frese, A. Keogh, S. Bisch-Knaden, E. Ayuni, N. Corazza, C. Weikert, S. Jakob, D. Erni, <b>J-F. Dufour</b> , T. Brunner, D. Candinas, D. Stroka. Activation of non-ischemic, hypoxia-inducible signalling pathways up-regulate cytoprotective genes in the murine liver. <i>J Hepatol</i> . 2007;47:538-45.	6.642	0.94
51.	P. Roth, C. Hammer, A-C. Pigué, M. Ledermann, <b>J-F. Dufour</b> , E. Waelti. Effects on hepatocellular carcinoma of doxorubicin-loaded immunoliposomes designed to target the VEGFR-2. <i>J Drug Target</i> . 2007;15:623-31.	2.030	0.475

52.	C. Hora, F. Negro, G. Leandro, CM Oneta, L. Rubbia-Brandt, B. Muellhaupt, B. Helbling, R. Malinverni, J-J. Gonvers, <b>J-F. Dufour</b> , the Swiss Hepatitis C Cohort Study Group. Connective tissue growth factor, steatosis and fibrosis in patients with chronic hepatitis C. <i>Liver Int.</i> 2008;28:370-6.	2.908	0.655
53.	A-C. Piguet, D. Semela, A. Keogh, L. Wilkens, D. Stroka, C. Stoupis, M.V. St-Pierre, <b>J-F. Dufour</b> . Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. <i>J Hepatol</i> 2008;49:78-87.	7.056	0.927
54.	V. Roh, A. Laemmle, U. Von Holzen, D. Stroka, <b>J-F. Dufour</b> , K. Hunt, D. Candinas, S. Vorburger. Dual induction of PKR with E2F-1 and IFN-alpha to enhance gene therapy against hepatocellular carcinoma. <i>Cancer Gene Ther.</i> 2008;15:636-44.	3.005	0.754
55.	S. Lenglet, F. Antigny, L. Vetterli, <b>J-F. Dufour</b> , MF Rossier. Hint2 is expressed in the mitochondria of H295R cells and is involved in steroidogenesis. <i>Endocrinology.</i> 2008;149:5461-9.	4.945	0.796
56.	B. Helbling, K. Overbeck, J-J. Gonvers, R. Malinverni, <b>J-F. Dufour</b> , J. Borovicka, M. Heim, A. Cerny, F. Negro, S. Bucher, M. Rickenbach, E. Renner, B. Muellhaupt. Host- rather than Virus-Related Factors Reduce Health-Related Quality of Life in Hepatitis C Virus Infection. <i>Gut.</i> 2008;57:1597-603.	9.766	0.964
57.	S. Dinges, I. Morard, M. Heim, <b>J-F. Dufour</b> , B. Müllhaupt, E. Giostra, PA. Clavien, G. Mentha, F. Negro; Swiss Association for the Study of the Liver (SASL 17). Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation. <i>Transpl Infect Dis.</i> 2009;1:33-9.	2.063	0.5
58.	ML. Balmer, K. Siegrist, A. Zimmermann, <b>J-F. Dufour</b> . Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with non-alcoholic steatohepatitis (NASH). <i>Liver International.</i> 2009;8:1184-8.	2.987	0.734
59.	PY. Bochud, T. Cai, K. Overbeck, M. Bochud, <b>J-F. Dufour</b> , B. Müllhaupt, J. Borovicka, M. Heim, D. Moradpour, A. Cern, R. Malinverni, P. Francioli, F. Negro; Swiss Hepatitis C Cohort Study Group. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. <i>J. Hepatol.</i> 2009; 51:655-66.	7.818	0.953
60.	AC. Piguet, D. Stroka, A. Zimmermann, <b>J-F. Dufour</b> . Hypoxia aggravates non-alcoholic steatohepatitis in mice lacking hepatocellular PTEN. <i>Clinical Science.</i> 2009;118:401-410.	3.982	0.8
61.	M. Seitz, S. Reichenbach, B. Möller, M. Zwahlen, PM. Villiger, <b>J-F. Dufour</b> . Hepatoprotective effect of TNF-a blockade in psoriatic arthritis: a cross-sectional study. <i>Ann Rheum Dis.</i> 2010;69:1148-50.	9.082	1
62.	C. Sgier, B. Müllhaupt, T. Gerlach, D. Moradpour, F. Negro, PJ. Malé, MH. Heim, R. Malinverni, A. Cerny, <b>J-F. Dufour</b> . Effect of antiviral therapy on circulating cytokeratin-18 fragments in patients with chronic hepatitis C. <i>J Viral hepatitis.</i> 2010;17:845-50.	3.502	0.743

63.	H. Chtioui, Olivier Mauerhofer, Beatrice Günther, <b>J-F. Dufour</b> . Macro-AST in an asymptomatic young patient. <i>Annals of Hepatology</i> . 2010;9:93-95.	1.867	0.357
64.	A. Rauch, Z. Kutalik, P. Descombes, T. Cai, J. di Julio, T. Mueller, M. Bochud, M. Battegay, E. Bernasconi, J. Borovicka, T. Calandra, S. Colombo, A. Cerny, <b>J-F. Dufour</b> , H. Furrer, H.F. Günthardt, M. Heim, B. Hirschel, R. Malinverni, D. Moradpour, B. Muellhaupt, A. Witteck, J. Beckman, T. Berg, S. Bergman, F. Negro, A. Telenti, P-Y. Bochud, and the Swiss HCV and HIV Cohort Studies. Genetic variation in IL28B Is Associated with Chronic Hepatitis C and Treatment Failure - A Genomewide Association Study. <i>Gastroenterology</i> . 2010;138:1338-45.	12.032	1
65.	K. Overbeck, <b>J-F. Dufour</b> , B. Müllhaupt, B. Helbling, J. Borovicka, R. Malinverni, M. Heim, D. Moradpour, A. Cerny, M. Rickenbach, F. Negro. Impact of international consensus guidelines on antiviral therapy of chronic hepatitis C patients in Switzerland. <i>Swiss Med Wkly</i> . 2010; 140:146-52.	1.823	0.711
66.	ML. Blamer, J. Joneli, A. Schoepfer, F. Stickel, W. Thormann, <b>J-F. Dufour</b> . Significance of serum adiponectin in patients with chronic liver diseases. <i>Clin Sci</i> . 2010;119:431-6.	4.613	0.846
67.	H. Chtioui, O. Maurhofer, B. Günther, <b>J-F. Dufour</b> . Macro-AST in an asymptomatic young patient. <i>Ann Hepatol</i> 2010;):93-95.	1.867	0.357
68.	<b>J-F. Dufour</b> , H. Hoppe, M. Heim, B. Helbling, O. Maurhofer, Z. Szucs-Farkas, R. Kikuth, M. Borner, D. Candinas, B. Saar. Continuous administration of sorafenib in combination with transarterial-chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. <i>The Oncologist</i> . 2010;15:1198-204.	5.826	0.881
69.	J. Martin, P. Romanque, O. Maurhofer, K. Schmitter, G. Ferrand, <b>J-F. Dufour</b> . Ablation of the tumor suppressor Hint1 is protective against ischemia reperfusion injury. <i>Hepatology</i> . 2011;53:243-52.	11.665	0.986
70.	C. Hora, P. Romanque, <b>J-F. Dufour</b> . Effect of Sorafenib on murine liver regeneration. <i>Hepatology</i> . 2011;53:577-86.	11.665	0.986
71.	A-C. Pignet, B. Saar, R. Hlushchuk, MV. St-Pierre, PM. McSheehy, V. Radojevic, M. Afthinos, L. Terraciano, V. Djonov, <b>J-F. Dufour</b> . Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. <i>Mol Cancer Ther</i> . 2011;10:1007-17.	5.226	0.856
72.	T. Cai, <b>J-F. Dufour</b> , B. Muellhaupt, T. Gerlach, M. Heim, D. Moradpour, A. Cerny, R. Malinverni, V. Kaddai, M. Bochud, F. Negro, P-Y. Bochud. Viral genotype-specific role of PNPLA3, PPARG, MTP, and IL28B in hepatitis C virus-associated steatosis. <i>J. Hepatology</i> . 2011;55:529-535.	9.264	0.959
73.	AD. Paterson, O. Maurhofer, D. Beyoglu, C. Lanz, KW Krausz, T. Pabst, FJ, Gonzalez, <b>J-F. Dufour</b> , J. Idle. Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomic and lipid profiling. <i>Cancer Res</i> . 2011;71:6590-600.	7.856	0.941

74.	CM. Lange, Z. Kutalik, K. Morikawa, S. Bibert, A. Cerny, G. Dollenmaier, <b>J-F. Dufour</b> , T. Gerlach, MH. Heim, R. Malinverni, B. Müllhaupt, F. Negro, D. Moradpour, PY. Bochud; the Swiss Hepatitis C Cohort Study Group. Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon- $\alpha$ and ribavirin therapy. <i>Hepatology</i> . 2012;55:1038-47.	12.003	0.986
75.	PY. Bochud, S. Bibert, Z. Kutalik, E. Patin, J. Guergnon, B. Nalpas, N. Goossens, L. Kuske, B. Müllhaupt, T. Gerlach, MH. Heim, D. Moradpour, A. Cerny, R. Malinverni, S. Regenass, G. Dollenmaier, H. Hirsch, G. Martinetti, M. Gorgiewski, M. Bourlière, T. Poynard, I. Theodorou, L. Abel, S. Pol, <b>J-F.Dufour</b> , F. Negro; on behalf of the Swiss Hepatitis C Cohort Study Group the ANRS HC EP 26 Genoscan Study Group. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. <i>Hepatology</i> . 2012;55:384-94.	12.003	0.986
76.	K. Baur, JC. Mertens, J. Schmitt, R. Iwata, B. Stieger, P. Frei, B. Seifert, HA. Bischoff Ferrari, A. von Eckardstein, B. Müllhaupt, A. Geier; Swiss Hepatitis C Cohort Study Group (incl. <b>J-F. Dufour</b> ). The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients. <i>Antivir Ther</i> . 2012;17:541-7.	3.073	0.724
77.	W. Sieghart, M. Pinter, B. Dauser, N. Rohr-Udilova, A-C. Piguët, G. Prager, H. Hayden, HP. Dienes, <b>J-F. Dufour</b> , M. Peck-Radosavljevic M. Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma. <i>J. Hepatol</i> . 2012;57:592-9.	9.858	0.945
78.	F. Girardin, Y. Daali, M. Gex-Fabry, M. Rebsamen, P. Roux-Lombard, A. Cerny, F. Bihl, J. Binek, D. Moradpour, F. Negro, J. Desmeules; Swiss Hepatitis C Cohort Study Group (incl. <b>J-F. Dufour</b> ). Liver kidney microsomal type 1 antibodies reduce the CYP2D6 activity in patients with chronic hepatitis C virus infection. <i>J Viral Hepat</i> . 2012;19:568-73.	3.082	0.721
79.	C. Lange, S. Bibert, Z. Kutalik, P. Burgisser, A. Cerny, <b>J-F. Dufour</b> , A. Geier, T. Gerlach, M. Heim, R. Malinverni, F. Negro, S. Regenass, K. Badenhoop, J. Bojunga, C. Sarrazin, S. Zeuzem, T. Müller, T. Berg, PY. Bochud, D. Moradpour; Swiss Hepatitis C Cohort Study Group. A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C. <i>PLoS One</i> . 2012;7:e40159.	3.73	0.882

80.	E. Patin E, Z. Kutalik, J. Guernon, S. Bibert, B. Nalpas, E. Jouanguy, M. Munteanu, L. Bousquet, L. Argiro, P. Halfon, A. Boland, B. Müllhaupt, D. Semela, <b>J-F. Dufour</b> , M. Heim, D. Moradpour, A. Cerny, R. Malinverni, H. Hirsch, G. Martinetti, V. Suppiah, G. Stewart, D. Booth, J. George, J. Casanova, C. Bréchet, C. Rice, A. Talal, I. Jacobson, M. Bourlière, I. Theodorou, T. Poynard, F. Negro, S. Pol, PY. Bochud, L. Abel; Swiss Hepatitis C Cohort Study Group, International Hepatitis C Genetics Consortium, French ANRS HC EP 26 Genosan Study Group. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. . 2012;143:1244-1252.	12.821	1
81.	L. Kuske, A. Mensen, B. Müllhaupt, F. Negro, D. Semela, D. Moradpour, PJ. Malé, M. Heim, R. Malinverni, A. Cerny, <b>J-F. Dufour</b> ; Swiss Hepatitis C Cohort Study. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma. Swiss Med Wkly. 2012 Aug 6;142:w13651.	1.821	0.682
82.	J. Martin, O. Maurhofer, N. Bellance, G. Benard, F. Graber, D. Hahn, A. Galinier, C. Hora, A. Gupta, G. Ferrand, H. Hoppeler, R. Rossignol, <b>J-F. Dufour</b> , MV. St-Pierre. Disruption of the histidine triad nucleotide-binding hint2 gene in mice affects glycemic control and mitochondrial function. Hepatology. 2013;105:1268-75.	12.003	0.986
83.	AJ. van der Meer, BJ. Veldt, JJ. Feld, H. Wedemeyer, <b>J-F. Dufour</b> , F. Lammert, A. Duarte-Rojo, EJ. Heathcote, MP. Manns, L. Kuske, S. Zeuzem, WP. Hofmann, RJ. de Knegt, BE. Hansen, HL. Janssen. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA.2012;308:2584-93.	29.978	0.987
84.	M. Rau, F. Stickel, S. Russmann, C. Manser, P. Becker, M. Weisskopf, J. Schmitt, M. Dill, <b>J-F. Dufour</b> , D. Moradpour, D. Semela, B. Müllhaupt, A. Geier. Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection. J Hepatol. 2012;11.027. 2013;58:669-75.	9.858	0.945
85.	S. Majumder, AC. Piguet, <b>J-F. Dufour</b> , S. Chatterjee. Study of the cellular mechanism of Sunitinib mediated inactivation of activated hepatic stellate cells and its implications in angiogenesis. EUR J Pharmacol. 2013;705:86-95.	2.73	0.644
86.	D. Beyoğlu, S. Imbeaud, O. Mauerhofer, P. Bioulac-Sage, J. Zucman-Rossi, <b>J-F. Dufour</b> , JR. Idle. Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. Hepatology. 2013;58:229-38.	11.711	0.962
87.	CM. Lange, S. Bibert, <b>J-F. Dufour</b> , C. Celleraï, A. Cerny, MH Heim, L. Kaiser, R. Malinverni, B. Müllhaupt, F. Negro, D. Semela, D. Moradpour, Z. Kutalik, PY. Bochud. Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma. J Hepatol. 2013;59:504-9.	10.59	0.949



88.	CM. Lange, D. Miki, H. Ochi, HD. Nischalke, J. Bojunga, S. Bibert, K. Morikawa, J. Gouttenoire, A. Cerny, <b>J-F. Dufour</b> , M. Gorgievski-Hrisoho, MH. Heim, R. Malinverni, B. Müllhaupt, F. Negro, D. Semela, Z. Kutalik, T. Müller, U. Spengler, T. Berg, K. Chayama, D. Moradpour, PY. Bochud. Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development. <i>PLoS One</i> . 2013;8:e64053.	3.057	0.836
89.	C. Erös de Bethlenfalva-Hora, JC. Mertens, AC. Piguët, J. Kettenbach, J. Schmitt, L. Terracciano, R. Weimann, <b>J-F. Dufour</b> , A. Geier. Radiofrequency Ablation Suppresses Distant Tumor Growth in a Novel Rat Model of Multifocal Hepatocellular Carcinoma. <i>Clin Sci (Lond)</i> . 2013;126:243.52.	4.996	0.879
90.	D. Ndiaye, M. Collado-Hilly, J. Martin, S. Prigent, <b>J-F. Dufour</b> , L. Combettes, G. Dupont. Characterization of the Effect of the Mitochondrial Protein Hint2 on Intracellular Ca(2+) dynamics. <i>Biophys J</i> . 2013; 105:1268-75.	3.632	0.761
91.	P. Frei, AK. Leucht, U. Held, R. Kofmehl, CN Manser, J. Schmitt, J. Mertens, M. Rau, K. Baur, T. Gerlach, F. Negro, M. Heim, D. Moradpour, A. Cerny, <b>J-F. Dufour</b> , B. Müllhaupt, A. Geier. Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon- $\alpha$ and ribavirin in chronic hepatitis C virus patients. <i>Liver Int</i> . 2013;34:551-7.	4.47	0.846
92.	AJ. van der Meer, BJ. Veldt, JJ. Feld, H. Wedemeyer, <b>J-F. Dufour</b> , F. Lammert, A. Duarte-Rojo, MP. Manns, S. Zeuzem, WP. Hofmann, RJ de Knegt, BE. Hansen, HL. Janssen. The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection. <i>J Viral Hepat</i> . 2013;21:568-77.	4.179	0.716
93.	YL. Liu, GL Patman, JB Leathart, A-C. Piguët, AD Burt, <b>J-F. Dufour</b> , CP Day, AK Daly, HL Reeves, QM Anstee. Carriage of the PNPLA3 rs738409C>G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. <i>J Hepatol</i> . 2014; 61:75-81.	4.122	0.81
94.	F. Al Hasani, M. Knoepfli, A. Gemperli, A. Kollar, V. Banz, J. Kettenbach, P. Jüni, <b>J-F. Dufour</b> . Factors affecting screening for hepatocellular carcinoma. <i>Ann Hepatol</i> . 2014;13:204-10.	1.678	0.215
95.	A.-C. Piguët, S. Majumder, U. Maheshwari, R. Manunathan, U. Saran, S. Chatterjee, <b>J-F. Dufour</b> . Everolimus is a potent inhibitor of activated hepatic stellate cell functions in vitro and in vivo, while demonstrating anti-angiogenic activities. <i>Clin Sci (Lond)</i> . 2014;126:775-84.	4.936	0.898
96.	R. Maan. AJ van der Meer, BE Hansen, JJ Feld, H Wedemeyer, <b>J-F. Dufour</b> , HF Zangneh, F. Lammert, MP Manns, S. ZeuzemHL. , Janssen, RJ de Knegt, BJ. Veldt. Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. <i>J Hepatol</i> . 2014;61:482-91.	12.486	0.949

97.	YL. Liu, HL. Reeves, AD. Burt, D. Tiniakos, S. McPherson, JB. Leathart, ME Allison, GJ Alexander, A-C. Piguët, R. Anty, P. Donaldson, GP. Aithal, S. Francque, L. Van Gaal, K. Clement, V. Ratziu, <b>J-F. Dufour</b> , CP Day, AK Daly, QM Anstee. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. <i>Nat Commun.</i> 2014;5:4309.	12.124	0.968
98.	D. Beyoğlu, KW. Krausz, J. Martin, O. Maurhofer, J. Dorow, U. Ceglarek, FJ. Gonzalez, <b>J-F. Dufour</b> , JR. Idle. Disruption of tumor suppressor gene Hint1 leads to remodeling of the lipid metabolic phenotype of mouse liver. <i>J Lipid Res.</i> 2014;55:2309-19.	4.81	0.814
99.	A. van der Meer, H. Wedemeyer, JJ. Feld, <b>J-F. Dufour</b> , S. Zeuzem, B. Hansen, H. Janssen. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. <i>JAMA.</i> 2014;312:1927-8.	16.538	0.968
100.	AJ. van der Meer, BE Hansen, G. Fattovich, JJ. Feld, H. Wedemeyer, <b>J-F. Dufour</b> , F. Lammert, A. Duarte-Rojo, MP. Manns, D. Ieluzzi, S. Zeuzem, WP. Hofmann, RJ de Knegt, BJ. Veldt, HL. Janssen. Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. <i>Gut.</i> 2015;64:322-31.	16.658	0.987
101	M. Zochowska, A-C. Piguët, J. Jemielity, J. Kowalska, E. Szolajska, <b>J-F. Dufour</b> , J. Chroboczek. Virus-like particle-mediated intracellular delivery of mRNA cap analog with in vivo activity against hepatocellular carcinoma. <i>Nanomedicine: Nanotechnology, Biology, and Medicine.</i> 2015;11:67-76.	4.727	0.88
102.	S. Rueger, P-Y. Bochud, <b>J-F. Dufour</b> , B. Mullhaupt, D. Semela, M. Heim, D. Moradpour, A. Cerny, R. Malinverni, D. Booth, V. Suppiah, J. George, L. Argiro, P. Halfon, M. Bourliere, A. Talal, I. Jacobson, E. Patin, B. Nalpas, T. Poynard, S. Pol, L. Abel, Z. Kutalik, F. Negro. Impact of common risk factors of fibrosis progression in chronic hepatitis C. <i>Gut.</i> 2015;64:1605-15.	16.658	0.987
103.	S. Zeuzem, <b>J-F. Dufour</b> , . M. Buti, V. Soriano, R. Buynak, P. Mantry, J. Taunk, J. Stern, R. Vinisko, JP. Gallivan, W. Böcher, FJ. Mensa; the SOUND-C3 study group. Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study. <i>Liver Int.</i> 2015;35:417-21.	4.116	0.797
104.	G. Diserens, M. Vermathen, C. Precht, NT. Broskey, C. Boesch, F. Amati, <b>J-F. Dufour</b> , P. Vermathen. Separation of small metabolites and lipids in spectra from biopsies by diffusion-weighted HR-MAS NMR: a feasibility study. <i>Analyst.</i> 2015;140:272-9.	3.885	0.855

105.	P. Ferenci, T. Asselah, GR. Foster, S. Zeuzem, C. Sarrazin, C. Moreno, D. Ouzan, M. Maevskaaya, F. Calinas, LE. Morano, J. Crespo, <b>J-F. Dufour</b> , M. Bourlière, K. Agarwal, D. Forton, M. Schuchmann, E. Zehnter, S. Nishiguchi, M. Omata, G. Kukolj, Y. Datsenko, M. Garcia, J. Scherer, AM. Quinson, J.O. Stern; on behalf of the STARTVerso1 study group. STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection. <i>J Hepatol.</i> 2015;62:1246-55.	12.486	0.949
106.	A-C. Piguet, U. Saran, C. Simillion, I. Keller, L. Terracciano, HL. Reeves, <b>J-F. Dufour</b> . Regular exercise decreases liver tumors development in hepatocyte-specific PTEN-deficient mice independently of steatosis. <i>J Hepatol</i> 2015;62:1296-303.	12.486	0.949
107.	R. Maan, AJ. van der Meer, BE. Hansen , JJ. Feld, H. Wedemeyer, <b>J-F. Dufour</b> , F. Lammert, MP. Manns, S. Zeuzem, HL. Janssen, RJ. de Knegt, BJ. Veldt. Risk of infections during interferon-based treatment in patients with chronic HCV infection and advanced hepatic fibrosis. <i>J Gastroenterol Hepatol.</i> 2015;30:1057-64.	0.165	0.025
108.	C. Toso, G. Meeberg, R. Hernandez-Alejandro, <b>J-F. Dufour</b> , P. Marotta, P. Majno, NM. Kneteman. Total Tumor Volume and Alpha Fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation. <i>Hepatology.</i> 2015;62:158-65.	13.246	0.962
109.	Q. Wang, P. Sachse, M. Semmo, M. Lokhande, M. Montani, <b>J-F. Dufour</b> , F. Zoulim, P. Klenerman, N. Semmo. T- and B-cell responses and previous exposure to hepatitis B virus in 'anti-HBc alone' patients. <i>J Viral Hepat.</i> 2015;22:1068-78.	4.122	0.81
110.	H. Wang, S. El Maadidi, J. Fischer, E. Grabski, S. Dickhöfer, S. Klimosch, SM. Flannery, A. Filomena, OO. Wolz, N. Schneiderhan-Marra, MW. Löffler, M. Wiese, T. Pichulik, B. Müllhaupt, D. Semela, <b>J-F. Dufour</b> , East-German and Swiss Hepatitis C Virus Study Groups, PY. Bochud, AG. Bowie, U. Kalinke, T. Berg, AN. Weber. A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance. <i>Hepatology.</i> 2015;62:1375-87.	13.246	0.962
111.	Richani M, Kolly P, Knoepfli M, Herrmann E, Zweifel M, von Tengg-Kobligk H, Candinas D, <b>J-F. Dufour</b> . Treatment allocation in hepatocellular carcinoma: Assessment of the BCLC algorithm. <i>Ann Hepatol.</i> 2015;15(1):82-90.	1.678	0.215
112.	C. Hirzel, G. Wandeler, M. Owczarek, M. Gorgievski-Hrisoho, <b>J-F. Dufour</b> , N. Semmo, S. Zürcher. Molecular epidemiology of hepatitis B virus infection in Switzerland: a retrospective cohort study. <i>BMC Infect Dis.</i> 2015;15:483.	2.768	0.571
113.	A-C. Piguet, M. Medová, A. Keogh, AA. Glück, DM. Aebersold, <b>J-F. Dufour</b> , Y. Zimmer. Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer. <i>Genes Cancer.</i> 2015;6:317-27.	0.913	0.06849

114.	S. Buhler, E. Giostra, C. Gbame, C. de Rham, B. Mullhaupt, <b>J-F. Dufour</b> , P. Majno, F. Negro, PY. Bochud, J. Villard; Swiss Hepatitis C Cohort Study (SCCS) and Swiss Transplant Cohort Study (STCS). A significant effect of the KIR ligand HLA-C on fibrosis progression in chronic C hepatitis with or without liver transplantation. <i>Liver Int.</i> 2016;36(9):1331-9.	4.116	0.797
115.	P. Kolly, H. Reeves, B. Sangro, M. Knöpfli, D. Candinas, <b>J-F. Dufour</b> . Assessment of the Hong Kong Liver Cancer Staging System in Europe. <i>Liver Int.</i> 2016;36:911-7.	4.116	0.797
116.	AJ. van der Meer, R. Maan, BJ. Veldt, JJ. Feld, H. Wedemeyer, <b>J-F. Dufour</b> , F. Lammert, A. Duarte-Rojo, MP. Manns, S. Zeuzem, W. Peter Hofmann, RJ. de Knegt, BE. Hansen, HL. Janssen. Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis. <i>J Gastroenterol Hepatol.</i> 2016;31(6):1168-76.	0.165	0.025
117.	L. Quteineh, PY. Bochud, D. Golshayan, S. Crettol, JP. Venetz, O. Manuel, Z. Kutalik, A. Treyer, R. Lehmann, NJ. Mueller, I. Binet, C. van Delden, J. Steiger, P. Mohacsi, <b>J-F. Dufour</b> , PM. Soccal, M. Pascual, CB Eap and The Swiss Transplant Cohort Study. CRT2 polymorphism as a risk factor for the incidence of metabolic syndrome in patients with solid organ transplantation. <i>Pharmacogenomics J.</i> 2016; 17(1):69-75.	3.815	0.805
118.	GR. Foster, P. Ferenci, T. Asselah, P. Mantry, <b>J-F. Dufour</b> , M. Bourlière, D. Forton, M. Maevskaya, D. Wright, EM. Yoshida, J. García-Samaniego, C. Oliveira, M. Wright, N. Warner, N. Sha, AM. Quinson, JO. Stern. Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirin. <i>J Viral Hepat.</i> 2016;23(3):227-31.	4.122	0.81
119.	J. Martin, ML. Balmer, S. Rajendran, O. Maurhofer, <b>J-F. Dufour</b> , MV. St-Pierre. Nutritional stress exacerbates hepatic steatosis induced by deletion of the histidine nucleotide-binding (Hint2) mitochondrial protein. <i>Am J Physiol Gastrointest Liver Physiol.</i> 2016 Apr 1;310(7):G497-509.	3.468	0.771
120.	D. Koeberle, <b>J-F. Dufour</b> , G. Demeter, Q. Li, K. Ribi, P. Samaras, P. Saletti, AD. Roth, D. Horber, M. Buehlmann, AD. Wagner, M. Montemurro, G. Lakatos, J. Feilchenfeldt, M. Peck-Radosavljevic, D. Rauch, B. Tschanz, G. Bodoky. Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). Swiss Group for Clinical Cancer Research (SAKK). <i>Ann Oncol.</i> 2016 May;27(5):856-61.	11.855	0.958

121.	M. Manns, D. Samuel, EJ. Gane, D. Mutimer, G. McCaughan, M. Buti, M. Prieto, JL. Calleja, M. Peck-Radosavljevic, B. Müllhaupt, K. Agarwal, P. Angus, EM. Yoshida, M. Colombo, M. Rizzetto, H. Dvory-Sobol, J. Denning, S. Arterburn, PS. Pang, D. Brainard, JG. McHutchison, <b>J-F. Dufour</b> , H. Van Vlierberghe, B. van Hoek, X. Fornis. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. SOLAR-2 investigators. <i>Lancet Infect Dis.</i> 2016 Jun;16(6):685-97.	19.846	1
122.	C. Zahnd, L. Salazar-Vizcaya, J-F. Dufour, B. Müllhaupt, G. Wandeler, R. Kouyos, J. Estill, B. Bertisch, A. Rauch, O. Keiser. Modelling the impact of deferring HCV treatment on liver-related complications in HIV coinfecting men who have sex with men. <i>Swiss HIV; Swiss Hepatitis C Cohort Studies. J Hepatol.</i> 2016 Jul;65(1):26-32.	12.486	0.949
123.	R. Maan, R. Zaim, AJ. van der Meer, JJ. Feld, H. Wedemeyer, <b>J-F. Dufour</b> , F. Lammert, MP. Manns, S. Zeuzem, BE. Hansen, HL. Janssen, BJ. Veldt, RJ. de Knegt, CA. de Groot. Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis. <i>J Gastroenterol Hepatol.</i> 2016;31(11):1851-1859.	0.165	0.025
124.	S. Zeuzem, P. Mantry, V. Soriano, RJ. Buynak, <b>J-F. Dufour</b> , PJ. Pockros, D. Wright, P. Angus, M. Buti, JO. Stern, W. Kadus, R. Vinisko, W. Böcher, FJ. Mensa. Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study. <i>Eur J Gastroenterol Hepatol.</i> 2016 Aug;28(8):923-6.	0.165	0.025
125.	N. Calo, P. Ramadori, C. Sobolewski, Y. Romero, C. Maeder, M. Fournier, P. Rantakari, FP. Zhang, M. Poutanen, <b>J-F. Dufour</b> , B. Humar, S. Nef, M. Foti. Stress-activated miR-21/miR-21* in hepatocytes promotes lipid and glucose metabolic disorders associated with high-fat diet consumption. <i>Gut.</i> 2016; 65(11):1871-1881.	16.658	0.987
126.	A. Teufel, T. Itzel, W. Erhart, M. Brosch, XY. Wang, YO. Kim, W. von Schönfels, A. Herrmann, S. Brückner, F. Stickel, <b>J-F. Dufour</b> , T. Chavakis, C. Hellerbrand, R. Spang, T. Maass, T. Becker, S. Schreiber, C. Schafmayer, D. Schuppan, J. Hampe. Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Disease and Liver Tissues From Patients. <i>Gastroenterology.</i> 2016;151(3):513-525.	18.392	1
127.	M. Munteanu, D. Tiniakos, Q. Anstee, F. Charlotte, G. Marchesini, E. Bugianesi, M. Trauner, M. Romero Gomez, C. Oliveira, C. Day, <b>J-F. Dufour</b> , S. Bellentani, Y. Ngo, S. Traussnig, H. Perazzo, O. Deckmyn, P. Bedossa, V. Ratzu, T. Poynard; FLIP Consortium and the FibroFrance Group. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. <i>Aliment Pharmacol Ther.</i> 2016;44(8):877-89.	7.286	0.961

128.	M. Linecker, P. Limani, P. Kambakamba, P. Kron, C. Tschuor, N. Calo, M. Foti, <b>J-F. Dufour</b> , R. Graf, B. Humar, PA. Clavien. Omega-3 Fatty Acids Protect Fatty and Lean Mouse Livers After Major Hepatectomy. <i>Ann Surg.</i> 2017Aug;266(2):324-332.	9.203	1
129.	L. Quteineh, PY. Bochud, D. Golshayan, S. Crettol, JP. Venetz, O. Manuel, Z. Kutalik, A. Treyer, R. Lehmann, NJ. Mueller, I. Binet, C. van Delden, J. Steiger, P. Mohacsi, <b>J-F. Dufour</b> , PM. Soccac, M. Pascual, CB. Eap and The Swiss Transplant Cohort Study. Treatment allocation in hepatocellular carcinoma: Assessment of the BCLC algorithm. <i>Pharmacogenomics J.</i> 2017; 69-75.	3.812	0.812
130.	A. Hari, HK. Nair, A. De Gottardi, I. Baumgartner, <b>J-F. Dufour</b> , A. Berzigotti. Diagnostic hepatic haemodynamic techniques: safety and radiation exposure. <i>Liver Int.</i> 2017 Jan;37(1):148-154.	4.5	0.813
131.	EB. Tapper, MS. Hughes, M. Buti, <b>J-F. Dufour</b> , S. Flamm, S. Firdoos, MP. Curry, NH. Afdhal. The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness Analysis. <i>Transplantation.</i> 2017 May;101(5):987-995.	3.96	0.925
132.	S. McPherson, T. Hardy, <b>J-F. Dufour</b> , S. Petta, M. Romero-Gomez, M. Allison, CP. Oliveira, S. Francque, L. Van Gaal, JM. Schattenberg, D. Tiniakos, A. Burt, E. Bugianesi, V. Ratziu, CP. Day, QM. Anstee. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. <i>Am J Gastroenterol</i> 2017 May;112:740-751.	10.231	0.938
133.	PL. Lévy, S. Duponchel, H. Eiseheid, J. Molle, M. Michelet, G. Diserens, M. Vermathen, P. Vermathen, <b>J-F. Dufour</b> , HP. Dienes, HM. Steffen, M. Odenthal, F. Zoulim, B. Bartosch. Hepatitis C virus infection triggers a tumor-like glutamine metabolism. <i>Hepatology.</i> 2017 Mar;65(3):789-803.	14.079	0.95
134.	E. Herrmann, D. Naehrig, M. Sassowsky, M. Bigler, J. Buijsen, I. Ciernik, D. Zwahlen, AF. Pellanda, A. Meister, P. Brauchli, S. Berardi, E. Kuettel, <b>J-F. Dufour</b> , DM. Aebersold, Swiss Group for Clinical Cancer Research (SAKK). External beam radiotherapy for unresectable hepatocellular carcinoma, an international multicenter phase I trial, SAKK 77/07 and SASL 26. <i>Radiat Oncol.</i> 2017 Jan;12(1):12.	2.862	0.717
135.	E. Kachaylo, C. Tschuor, N. Calo, N. Borgeaud, P. Limani, A-C. Piguet, <b>J-F. Dufour</b> , M. Foti, R. Graf, PA. Clavien, B. Humar. PTEN downregulation promotes $\beta$ -oxidation to fuel hypertrophic liver growth after hepatectomy in mice. <i>Hepatology.</i> 2017 Sep;66(3):908-921.	14.079	0.95
138.	P. Kolly, M. Knöpfli, <b>J-F. Dufour</b> . Effect of Smoking on Survival of Patients with Hepatocellular Carcinoma. <i>Liver Int.</i> 2017 Nov; 37(11):1682-1687.	4.5	0.813

139.	P. Kolly, O. Waidmann, J. Vermehren, C. Moreno, I. Vögeli, T. Berg, D. Semela, S. Zeuzem, <b>J-F. Dufour</b> . Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study. <i>J Hepatol.</i> 2017;67:876-878.	14.911	0.962
140.	N. Saigi-Morgui, L. Quteineh, PY. Bochud, S. Crettol, Z. Kutalik, NJ. Mueller, I. Binet, C. Van Delden, J. Steiger, P.Mohacsi, <b>J-F. Dufour</b> , PM. Soccacal, M. Pascual, CB. Eap; Swiss Transplant Cohort Study. Genetic and clinic predictors of new onset diabetes mellitus after transplantation. <i>Pharmacogenomics J.</i> 2017;10.1038.	3.812	0.812
141.	U. Saran, M. Guarino, S. Rodríguez, C. Simillion, M. Montani, M. Foti, B. Humar, M.V. St-Pierre, <b>J-F. Dufour</b> . Anti-tumoral effects of exercise on hepatocellular carcinoma growth. <i>Hepatol Commun.</i> 2018 Mar;2(5):607-620.		
142.	O. Keiser, F. Giudici, B. Müllhaupt, C. Junker, <b>J-F. Dufour</b> , D. Moradpour, P. Bruggmann, B. Terziroli, D. Semela, M. Brezzi, B. Bertisch, J. Estill, F. Negro, A. Spoerri; Swiss Hepatitis C Cohort Study and the Swiss National Cohort. Trends in hepatitis C-related mortality in Switzerland. <i>J Viral Hepat.</i> 2018;25:152-160.		
143.	C. Margini, G. Murgia, G. Stirnimann, A. De Gottardi, N. Semmo, S. Casu, J. Bosch, <b>J.-F. Dufour</b> , A. Berzigotti. Prognostic Significance of Controlled Attenuation Parameter in Patients With Compensated Advanced Chronic Liver Disease. <i>Hepatol Commun.</i> 2018 Jul 24;2(8):929-940.		
144.	A. Gmür, P. Kolly, M. Knöpfli, <b>J-F. Dufour</b> . FACT-Hep increases the accuracy of survival prediction in HCC patients when added to ECOG Performance Status. <i>Liver Int.</i> 2018 Aug;38(8):1468-1474.		
145.	M. Puoti, GR. Foster, S. Wang, D. Mutimer, E. Gane, C. Moreno, TT. Chang, SS. Lee, R. Marinho, <b>J-F. Dufour</b> , S. Pol, C. Hezode, SG. Gordon, SI Strasser, PJ. Thuluvath, Z. Zhang, S. Lovell, T. Pilot-Matias, FJ. Mensa. High SVR12 with 8-week and 12-week Glecaprevir/Pibrentasvir: Integrated Analysis of HCV Genotype 1-6 Patients Without Cirrhosis. <i>J Hepatol.</i> 2018 Aug;69(2):293-300.		
146.	M. Linecker, L. Frick, P. Kron, P. Limani, P. Kambakamba, C. Tschuor, M. Langiewicz, E. Kachaylo, Y. Tian, M.A. Schneider, U. Ungethüm, N. Calo, M. Foti, <b>J.-F. Dufour</b> , R. Graf, B. Humar, P. A. Clavien. Exercise Improves Outcomes of Surgery on Fatty Liver in Mice: A Novel Effect Mediated by the AMPK Pathway. <i>Ann Surg.</i> 2018 Aug 22. doi: 10.1097/ SLA. 0000000000002904.		
147.	R. Rajasekaran, A.Felser, J-M. Nuoffer, <b>J-F. Dufour</b> , MV. St-Pierre. The histidine triad nucleotide-binding protein 2 (HINT-2) positively regulates hepatocellular energy metabolism. <i>FASEB Journal</i> 2018 Sep;32(9):5143-5161.		
148.	K. Agarwal, L. Castells, B. Müllhaupt, W.M.C. Rosenberg, B. McNabb, S. Arterburn, G. Camus, J. McNally, L.-M. Stamm, D.-M. Brainard, G. Mani Subramanian, Z. Mariño, <b>J.-F. Dufour</b> , X. Forns. Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients. <i>J Hepatol.</i> 2018 Sep;69(3):603-607.		

149.	A. Geier, M. Eichinger, G. Stirnimann, D. Semela, F. Tay, B. Seifert, O. Tschopp, H. Bantel, D. Jahn, E. Marques Maggio, L. Saleh, H. A. Bischoff-Ferrari, B. Müllhaupt, <b>J.-F. Dufour</b> . Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. <i>Scand J Gastroenterol</i> . 2018 Sep;53(9):1114-1120.		
150.	H. Y. Lim, P. Merle, K. H. Weiss, T. Yau, P. Ross, V. Mazzaferro, J. F. Blanc, Y. T. Ma, C. J. Yen, J. Kocsis, S. P. Choo, W. Sukeepaisarnjaroen, R. Gérolami, <b>J.-F. Dufour</b> , E. J. Gane, B. Y. Ryoo, M. Peck-Radosavljevic, T. Dao, W. Yeo, W. Lamlerthton, S. Thongsawat, M. Teufel, K. Roth, D. Reis, B. H. Childs, H. Krissel, J. M. Llovet. Phase II Studies with Refameti-nib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma. <i>Clin Cancer Res</i> . 2018 Oct 1;24(19):4650-4661.		
151.	S. Beckebaum, K. Herzer, A. Bauhofer, W. Gelson, P. De Simone, R. de Man, C. Engelmann, B. Müllhaupt, J. Vionnet, M. Salizzoni, R. Volpes, G. Ercolani, L. De Carlis, P. Angeli, P. Burra, <b>J.-F. Dufour</b> , M. Rossi, U. Cillo, U. Neumann, L. Fischer, G. Niemann, L. Toti, G. Tisone. Recurrence of Hepatitis B Infection in Liver Transplant Patients Receiving Long-Term Hepatitis B Immunoglobulin Prophylaxis. <i>Ann Transplant</i> . 2018 Nov 13;23:789-801.		
152.	N. I. Caversaccio, M. D. Reina Caro, R. Prince, M. Müller, C. S. Lewis, V. Y. Bogdanov, <b>J.-F. Dufour</b> , A. Angelillo-Scherrer. Alternatively spliced tissue factor levels are elevated in the plasma of patients with chronic liver diseases. <i>Eur J Gastroenterol Hepatol</i> . 2018 Dec;30(12):1470-1475.		
153.	L. Quteineh, A. Wójtowicz, P. Y. Bochud, S. Crettol, F. Vandenberghe, J. P. Venetz, O. Manuel, D. Golshayan, R. Lehmann, N. J. Mueller, I. Binet, C. van Delden, J. Steiger, P. Mohacsi, <b>J.-F. Dufour</b> , P. M. Socal, Z. Kutalik, P. Marques-Vidal, P. Vollenweider, M. Recher, C. Hess, M. Pascual, C. B. Eap; Swiss Transplant Cohort Study. Genetic immune and inflammatory markers associated with diabetes in solid organ transplant recipients. <i>Am J Transplant</i> . 2019 Jan;19(1):238-246.		
154.	N. Saigi-Morgui, L. Quteineh, P. Y. Bochud, S. Crettol, Z. Kutalik, N. J. Mueller, I. Binet, C. van Delden, J. Steiger, P. Mohacsi, <b>J.-F. Dufour</b> , P.M. Socal, M. Pascual, C. B. Eap; Swiss Transplant Cohort Study. Genetic and clinic predictors of new onset diabetes mellitus after transplantation. <i>Pharmacogenomics J</i> . 2019 Feb;19(1):53-64.		



B. Editorials, Reviews; Guidelines:

\*IF \*\*Ranking

1.	<b>J-F. Dufour</b> , MM. Kaplan. Muddying the water: Wilson's challenges will not soon disappear. <i>Gastroenterology</i> . 1997;113:348-50.	10.250	
2.	<b>J-F. Dufour</b> , C. Redaelli. Survival pathways and preconditioning in liver transplantation. <i>Transplant Immunology</i> . 2002;9:239-241.	1.349	
3.	<b>J-F. Dufour</b> , MV. St-Pierre. Phytotherapeutika in Gastroenterologie und Hepatologie. <i>Therapeutische Umschau</i> . 2002;59:313-316.		
4.	P. Allemann, B. Burckhardt, <b>J-F. Dufour</b> . Transplantation for alcoholic liver disease : the wrong arguments. <i>Swiss Medical Weekly</i> . 2002;132:296-7.	0.770	
5.	C. Oneta, <b>J-F. Dufour</b> . Treatment options in non-alcoholic steatohepatitis according to pathogenic considerations. <i>Swiss Medical Weekly</i> . 2002; 132:493-505.	0.770	
6.	<b>J-F. Dufour</b> . Hepatocellular antifreeze carrier. <i>J Hepatol</i> 2003;39:460-2.	5.283	0.915
7.	E. Schmied, <b>J-F. Dufour</b> , S. Euvrard. Nontumoral dermatologic problems after liver transplantation. <i>Liver Transpl</i> 2004;10:331-9.	3.984	0.964
8.	D. Semela, <b>J-F. Dufour</b> . Angiogenesis and hepatocellular carcinoma. <i>J Hepatol</i> 2004;41:864-80.	4.816	0.935
9.	<b>J-F. Dufour</b> , M. Fey. What is the current treatment of post-transplant lymphoproliferative disorders after liver transplantation? <i>J Hepatol</i> 2006;44:23-6.	6.073	0.936
10.	A. De Gottardi, <b>J-F. Dufour</b> . Die Ösophagus-/Fundus-Varizen-Blutung. <i>Therapeutische Umschau</i> . 2006;63:295-300.	6.642	0.94
11.	<b>J-F. Dufour</b> . Met-hodology. <i>J Hepatology</i> 2007;46:748-8.	6.642	0.94
12.	<b>J-F. Dufour</b> . NASH and thiazolidinediones: not to be taken lightly. <i>J Hepatology</i> 2007;47:451-3.	6.642	0.94
13.	<b>J-F. Dufour</b> , O. Huber, S. Kozma, R. Toftgard. Tumour suppressors in liver carcinogenesis. <i>J Hepatol</i> . 2007;47:860-7.	6.642	0.94
14.	J. Martin, <b>J-F. Dufour</b> . Tumor suppressors and hepatocellular carcinoma. <i>World J Gastroenterology</i> . 2008;14:1720-33.	2.081	0.436
15.	P. Romanque, A-C. Piguët, <b>J-F. Dufour</b> . Targeting vessels to treat hepatocellular carcinoma. <i>Clin Sci</i> 2008;114:467-77.	4.187	0.852
16.	M. Balmer, <b>J-F. Dufour</b> . Treatment of hypercholesterolemia in patients with primary biliary cirrhosis might be more beneficial than indicated. <i>Swiss Med Wkly</i> . 2008;138:415-9.	1.436	0.495
17.	B. Strelbel, <b>J-F. Dufour</b> . Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. <i>Expert Rev Anticancer Ther</i> . 2008;8:1743-9.	2.296	0.381
18.	<b>J-F. Dufour</b> . The evasive promise of antiangiogenic therapy. <i>J Hepatol</i> . 2009;51:970-2.	7.818	0.953
19.	<b>J-F. Dufour</b> . Treat the bones and get less rejection. <i>Liver International</i> . 2010;30:337-8.	3.84	0.786
20.	<b>J-F. Dufour</b> , P. Johnson. Liver Cancer: From Molecular Pathogenesis to new therapies. Summary of a Single Topic Conference. <i>J. Hepatol</i> . 2010;52:296-304.	9.334	0.957

21.	<b>J-F. Dufour.</b> Vitamin E for non-alcoholic steatohepatitis: ready for prime time? <i>Hepatology</i> . 2010;52:789-92.	10.885	0.986
22.	J. Martin, <b>J-F. Dufour.</b> Abnormal nitrosothiol metabolism in hepatocellular carcinoma. 2011;54:579-80.	9.264	0.959
23.	M. Haedrich, <b>J-F. Dufour.</b> UDCA for NASH: end of the story? <i>J. Hepatol.</i> 2011;54:856-8.	9.264	0.959
24.	A-C. Piguet, <b>J-F. Dufour.</b> PI(3)K/PTEN/AKT Pathway. <i>J Hepatol.</i> 2011;54:1317-9.	9.264	0.959
25.	J. Martin, MV. St-Pierre, <b>J-F. Dufour.</b> HIT proteins, mitochondria and cancer. <i>Biochim Biophys Acta.</i> 2011;1807:626-632.	3.022	0.559
26.	ML. Balmer, <b>J-F. Dufour.</b> Non-alcoholic steatohepatitis – from NAFLD to MAFLD. <i>Ther Umsch.</i> 2011;68:183-8.	-	-
27.	FY. Yao, S. Breitenstein, CE. Broeschl, <b>J-F. Dufour</b> , M. Sherman. Does a patient qualify for liver transplantation after down-staging of hepatocellular carcinoma. <i>Liver Transplantation</i> 2011;17:S109-116.	3.386	0.929
28.	MV. St-Pierre, <b>J-F: Dufour.</b> Biomarkers for hepatocellular apoptosis in the management of liver diseases. <i>Curr. Pharm. Biotechnol.</i> 2012; 2221-2227.	-	-
29.	B. Morell, <b>J-F. Dufour.</b> Liver transplantation - when and for whom it should be performed. <i>Ther Umsch.</i> 2011;68:707-13.	2.69	0.63
30.	Swiss Association for the Study of the Liver. Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir. <i>Swiss Med Wkly.</i> 2012;24;142:w13516.	1.821	0.682
31.	<b>J-F. Dufour.</b> TACE with or without systemic therapy? <i>J Hepatol.</i> 2012;56:1224-5.	9.858	0.945
32.	<b>J-F. Dufour.</b> Anti-angiogenic therapy for HCC. <i>Minerva Gastroenterol Dietol.</i> 2012;58:81-6.	-	-
33.	European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. <i>J Hepatol.</i> 2012;56:908-43.	9.858	0.945
34.	F. Liechti, <b>J-F. Dufour.</b> Treatment of NASH with ursodeoxycholic acid: <i>Cons. Clin Res Hepatol Gastroenterol.</i> 2012;36 Suppl 1:S46-52.	1.348	0.178
35.	L. Bolondi, A. Burroughs, <b>J-F. Dufour</b> , PR. Galle, V. Mazzaferro, F. Piscaglia, JL. Raoul, B. Sangro. Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions. <i>Semin Liver Dis.</i> 2012;32:348-59.	8.274	0.932
36.	A-C. Bürgi, <b>J-F. Dufour.</b> Treatment of non-alcoholic steatohepatitis. <i>Rev Prat.</i> 2012;62:1425-7.	-	
37.	<b>J-F. Dufour</b> , C-reactive protein, a prognostic marker in HCC. <i>Hepatology.</i> 2013;57:2103-5.	11.19	0.973
38.	<b>J-F. Dufour</b> , Modern hepatomancy. <i>Gastroenterology.</i> 2013;144:876-8.	13.926	1
39.	<b>J-F. Dufour</b> , I. Bargellini, N. De Maria, P. De Simone, I. Goulis, RT. Marinho. Intermediate hepatocellular carcinoma : current treatments and future perspectives. <i>Ann Oncol.</i> 2013;Suppl 2:ii24-9.	6.578	0.915

40.	AB. Leichtle, <b>J-F. Dufour</b> , GM. Fiedler. Potentials and pitfalls of clinical peptidomics and metabolomics. Swiss Med Wkly. 2013;143:w13801.	1.877	0.678
41.	S. Tonko, <b>J-F. Dufour</b> , (Hepatology scores). Therapeutische Umschau. 2013;70:577-9.	-	
42.	<b>J-F. Dufour</b> . Hepatology highlights. Hepatology. 2013;58:1869-70.	11.19	0.973
43.	<b>J-F. Dufour</b> . Hepatology highlights. Hepatology. 2014;59:1-3.	13.246	0.962
44.	<b>J-F. Dufour</b> . Hepatology highlights. Hepatology. 2014;59:357-9.	13.246	0.962
45.	<b>J-F. Dufour</b> . Hepatology highlights. Hepatology. 2014;59:743-5.	13.246	0.962
46.	<b>J-F. Dufour</b> . Hepatology highlights. Hepatology. 2014;59:1217-9.	13.246	0.962
47.	H. Perazzo, T. Poynard, <b>J-F. Dufour</b> . The interactions of nonalcoholic fatty liver disease and cardiovascular disease. Clin Liver Dis. 2014;18:233-48.	13.246	0.962
48.	<b>J-F. Dufour</b> . Hepatocellular carcinoma. Sorafenib--for once age is not an issue. Nat Rev Gastroenterol Hepatol. 2014;11:273-4.	13.246	0.962
49.	<b>J-F. Dufour</b> . Hepatology highlights. Hepatology. 2014;59:1721-2.	13.246	0.962
50.	<b>J-F. Dufour</b> . Hepatology highlights. Hepatology. 2014;59:2059-61.	13.246	0.962
51.	<b>J-F. Dufour</b> . Hepatology highlights. Hepatology. 2014;60:1-3.	13.246	0.962
52.	<b>J-F. Dufour</b> . Hepatology highlights. Hepatology. 2014;60:445-7.	13.246	0.962
53.	<b>J-F. Dufour</b> . Hepatology highlights. Hepatology. 2014;60:773-5.	13.246	0.962
54.	<b>J-F. Dufour</b> . Hepatology highlights. Hepatology. 2014;60:1119-20.	13.246	0.962
55.	<b>J-F. Dufour</b> . Hepatology highlights. Hepatology. 2014;60:1455-7.	13.246	0.962
56.	<b>J-F. Dufour</b> . Hepatology highlights. Hepatology. 2014;60:1803-5.	13.246	0.962
57.	<b>J-F. Dufour</b> . Hepatology highlights. Hepatology. 2015;61:1-3.	13.246	0.962
58.	G. Wandeler, <b>J-F. Dufour</b> , P. Bruggmann, A. Rauch. Hepatitis C: a changing epidemic. Swiss Med Wkly. 2015;145:w14093.	13.246	0.962
59.	<b>J-F. Dufour</b> . Hepatology highlights. Hepatology. 2015;61:411-2.	13.246	0.962
60.	<b>J-F. Dufour</b> . Hepatology highlights. Hepatology. 2015;61:741-3.	13.246	0.962
61.	<b>J-F. Dufour</b> . Hepatology highlights. Hepatology. 2015;61:1101-3.	13.246	0.962
62.	<b>J-F. Dufour</b> . Hepatology highlights. Hepatology. 2015;61:1449-51.	13.246	0.962
63.	<b>J-F. Dufour</b> . Hepatology highlights. Hepatology. 2015;61:1773-5.	13.246	0.962
64.	<b>J-F. Dufour</b> . Hepatology highlights. Hepatology. 2015;62:1-3.	13.246	0.962
65.	<b>J-F. Dufour</b> . Hepatology highlights. Hepatology. 2015;62:327-9.	13.246	0.962
66.	<b>J-F. Dufour</b> . Hepatology highlights. Hepatology. 2015;62:663-5.	13.246	0.962
67.	U. Saran, B. Humar, P. Kolly, <b>J-F. Dufour</b> . Hepatocellular carcinoma and lifestyles. J Hepatol. 2015.	12.486	0.949
68.	U. Saran, M. Foti, <b>J-F. Dufour</b> . Cellular and molecular effects of the mTOR inhibitor everolimus. Clin Sci. 2015.	4.936	0.898
69.	A. Berzigotti, U. Saran, <b>J-F. Dufour</b> . Physical activity and liver diseases. Hepatology.2015.	13.246	0.962
70.	C. Pocha, P. Kolly, <b>J-F. Dufour</b> . Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: A Problem of Growing Magnitude. Semin Liver Dis. 2015;35:304-17.	5.5	0.861
71.	<b>J-F. Dufour</b> . Time to Abandon NASH? Hepatology. 2016;63:9-10.	13.246	0.962
72.	C. Margini, <b>J-F. Dufour</b> . The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment. Liver Int. 2016; 36(3):317-24.	4.116	0.797

73.	I. Bartella, <b>J-F. Dufour</b> . Clinical Diagnosis and Staging of Intrahepatic Cholangiocarcinoma. <i>J Gastrointest Liver Dis.</i> 2015;24:481-9.	1.837	0.241
74.	<b>J-F. Dufour</b> . Hepatology highlights. <i>Hepatology.</i> 2015;62:985-7.	13.246	0.962
75.	<b>J-F. Dufour</b> . Hepatology highlights. <i>Hepatology.</i> 2015;62:1331-3.	13.246	0.962
76.	<b>J-F. Dufour</b> . Hepatology highlights. <i>Hepatology.</i> 2015;62:1649-51.	13.246	0.962
77.	<b>J-F. Dufour</b> . Hepatology highlights. <i>Hepatology.</i> 2016;63:9-10.	13.246	0.962
78.	Surveillance for Hepatocellular Carcinoma in Patients with NASH. P. Kolly, <b>J-F. Dufour</b> . <i>Diagnostics (Basel).</i> 2016; 6(2). pii: E22.	-	
79.	<b>J-F. Dufour</b> . Hepatology highlights. <i>Hepatology.</i> 2016;63:679-81.	13.246	0.962
80.	<b>J-F. Dufour</b> . Hepatology highlights. <i>Hepatology.</i> 2016;63:1026-40.	13.246	0.962
81.	<b>J-F. Dufour</b> . Hepatology highlights. <i>Hepatology.</i> 2016;63:1065-67.	13.246	0.962
82.	<b>J-F. Dufour</b> . Hepatology highlights. <i>Hepatology.</i> 2016;63:1405-7.	13.246	0.962
83.	<b>J-F. Dufour</b> . Hepatology highlights. <i>Hepatology.</i> 2016;63:1749-51.		
84.	A. Teufel, <b>J-F. Dufour</b> . Two-Step Forward Genetic Screen in Mice Identifies the Ral Pathway as a Central Drug Target in Hepatocellular Carcinoma. <i>Gastroenterology.</i> 2016; 151(2):231-3.	18.392	1
85.	<b>J-F. Dufour</b> . Hepatology highlights. <i>Hepatology.</i> 2016;64:1-3.	13.246	0.962
86.	<b>J-F. Dufour</b> . Hepatology highlights. <i>Hepatology.</i> 2016;64:325-7.	13.246	0.962
87.	<b>J-F. Dufour</b> . Hepatology highlights. <i>Hepatology.</i> 2016;64:703-5.	13.246	0.962
88.	<b>J-F. Dufour</b> . Hepatology highlights. <i>Hepatology.</i> 2016;64:1011-3.	13.246	0.962
89.	<b>J-F. Dufour</b> . Hepatology highlights. <i>Hepatology.</i> 2016;64:1395-7.	13.246	0.962
90.	<b>J-F. Dufour</b> . Hepatology highlights. <i>Hepatology.</i> 2016;64:1829-30.	13.246	0.962
91.	H. Perazzo, <b>J-F. Dufour</b> . The therapeutic landscape of non-alcoholic steatohepatitis. <i>Liver Int</i> 2017 May;37(5):634-647.	4.116	0.797
92.	A. Scherer, <b>J-F. Dufour</b> . Treatment of Non-Alcoholic Fatty Liver Disease. <i>Dig Dis.</i> 2016;34 Suppl 1:27-31.	1.775	0.228
93.	L. von Köckritz, <b>J-F. Dufour</b> . Management of chronic hepatitis C in 2017. <i>Hamostaseologie Aug.</i> 2017;37(3):186-195.	1.345	0.197
94.	<b>J-F. Dufour</b> . Hepatology highlights. <i>Hepatology.</i> 2017;65:1-3.	14.079	0.95
95.	<b>J-F. Dufour</b> . Hepatology highlights. <i>Hepatology.</i> 2017;65:399-400	14.079	0.95
96.	<b>J-F. Dufour</b> . Hepatology highlights. <i>Hepatology.</i> 2017;65:761-762	14.079	0.95
97.	<b>J-F. Dufour</b> . Hepatology highlights. <i>Hepatology.</i> 2017;65:1081-1083	14.079	0.95
98.	<b>J-F. Dufour</b> . Hepatology highlights. <i>Hepatology.</i> 2017;65:1429-1431	14.079	0.95
99.	<b>J-F. Dufour</b> . Hepatology highlights. <i>Hepatology.</i> 2017;65:1783-1784.	14.079	0.95
100.	P. Kolly, <b>J-F. Dufour</b> . Patients with hepatocellular carcinoma: Your address matters! <i>J Hepatol.</i> 2017 Mar;66(3):480-481.	14.911	0.962
101.	H. Perazzo, <b>J-F. Dufour</b> . The therapeutic landscape of non-alcoholic steatohepatitis. <i>Liver Int.</i> 2017 May;37(5):634-647.	4.5	0.813
102.	P. Kolly, O. Waidmann, J. Vermehren, C. Moreno, I. Vögeli, T. Berg, D. Semela, S. Zeuzem, <b>J-F. Dufour</b> . Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study. <i>J Hepatol.</i> 2017 Oct;67(4):876-878.	14.911	0.962
103.	D. Segna, <b>J-F. Dufour</b> . Other Extrahepatic Manifestations of Hepatitis C Virus Infection (Pulmonary, Idiopathic Thrombocytopenic Purpura, Nondiabetes Endocrine Disorders). <i>Clin Liver Dis.</i> 2017 Aug;21(3):607-629.	4.771	0.837

104.	C. Rauh, <b>J-F. Dufour</b> . Nichtalkoholische Fettlebererkrankung (NAFLD). Therapeutische Umschau 2017 Jul;74(3):87-92.	-	
105.	S. Klein, <b>J-F. Dufour</b> . Nonalcoholic fatty liver disease and hepatocellular carcinoma. Hepat Oncol. 2017 Jul;4(3):83-98	-	
106.	A. Gerbes, F. Zoulim, H. Tilg, <b>J-F. Dufour</b> , J. Bruix, V. Paradis, R. Salem, M. Peck-Radosavljevic, PR. Galle, TF. Greten, JC. Nault, MA. Avila. Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma. Gut. 2018 Feb;67(2):380-388.		
107.	S. Miethe, M. Guarino, F. Alhamdan, H.U. Simon, H. Renz, <b>J.-F. Dufour</b> , D. P. Potaczek, H. Garn. Effects of obesity on asthma: immunometabolic links. Pol Arch Intern Med. 2018 Aug 31;128(7-8):469-477.		
108.	M. Cassano, <b>J.-F. Dufour</b> . Inflammation and Microbiota Fingerprint: Delphi's Oracle for Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma? Hepatology. 2019 Jan; 69(1):12-15.		

C. Letters to the Editor, Case reports:

		* <b>IF</b>	** <b>Ranking</b>
1.	P. Beris, <b>J-F. Dufour</b> . Treatment of autoimmune thrombocytopenic purpura. Letter. N. Engl. J. Med. 1989;321:760-761.	-	
2.	C. Seiler, <b>J-F. Dufour</b> . Survival after liver transplantation. Lancet. 2001;357:72.	13.251	
3.	F. Mosimann, J-J. Gonvers, G. Mentha, E. Giostra, C. Seiler, <b>J-F. Dufour</b> , P. Morel. Liver allocation in Switzerland. Liver Transplantation. 2002;8:88.	3.786	
4.	P. Romanque, F. Stickel, <b>J-F. Dufour</b> . Disproportionally high transient elastography Values in patients with autoimmune hepatitis. Liver International 2008;8:1177-8.	2.908	0.655
5.	M. Röther, <b>J-F. Dufour</b> , B. Schnüriger. An uncommon cause of a focal liver lesion. Gastroenterology. 2013;144:510-659.	13.926	1
6.	R. Thattil, <b>J-F. Dufour</b> . Hepatocellular carcinoma in a non-cirrhotic patient with Wilson's disease. World J Gastroenterol. 2013;19:2110-3.	2.433	0.527
7.	U. Bechtel-Grosch, C. Beguelin, S. Berezowska, <b>J-F. Dufour</b> , Takala J, Schefold JC. Fulminant hepatic and multiple organ failure following acute viral tonsillitis: a case report. J Med Case Rep. 2016;10:7.	-	
8.	P. Kolly, <b>J-F. Dufour</b> . A strong message is needed to address the issue of HCC recurrence after DAA therapy. J Hepatol. 2016 Dec;65(6):1268-1269.	12.486	0.0949
9.	R. Bill, M. Montani, B. Blum, <b>J-F. Dufour</b> , R. Escher, M. Bühlmann. Favorable response to mTOR inhibition in a young patient with unresectable fibrolamellar carcinoma of the liver. Hepatology. 2018 Jul;68(1):384-386. doi: 10.1002/hep.29853.		

10.	B. Trueb, L. Zhuang, I. Keller, L. von Köckritz, S. Kuchen, <b>J.-F. Dufour</b> , P. M. Villiger. Coincidence of NOD2-Associated Autoinflammatory Disease (Yao Syndrome) and HCV Infection With Fatal Consequences: Interaction Between Genes and Environment. <i>J Clin Rheumatol</i> . 2018 Dec 28. doi: 10.1097/RHU.0000000000000963.		
11.	G. Beldi, D. Vuitton, A. Lachenmayer, B. Heyd, <b>J.-F. Dufour</b> , C. Richou, D. Candinas, S. Bresson-Hadni. Is ex vivo liver resection and autotransplantation a valid alternative treatment for end-stage hepatic alveolar echinococcosis in Europe? <i>J Hepatol</i> . 2019 Feb 1. pii: S0168-8278(18)32630-8. doi: 10.1016/j.jhep.2018.12.011.		

\* **Impact factor**

\*\* **Maximum-Ranking according to Journal Index**

([www.medizin.unibe.ch/forschung/journalindex/index\\_ger.html](http://www.medizin.unibe.ch/forschung/journalindex/index_ger.html))

#### D. Book's chapters, electronic media:

1. J. Cotting, **J.-F. Dufour**, P. Lentze, J. Reichen. Ursodeoxycholate in the treatment of cholestasis in cystic fibrosis. In 'Paediatric Cholestasis.' Falk Symposium 63;345-353. Kluwer academic publishers, 1992.
2. **J.-F. Dufour**, M. Kaplan. The antifibrotic effect of interferon in the treatment of hepatitis C: an unanticipated but important endpoint. *Medscape Gastroenterology (eMed Journal)*. May/June 2000 Vol 2 Number 3.
3. **J.-F. Dufour**, E. Schmied. Dermatologic problems in patients, who have undergone liver transplantation. In: UpToDate, Rose, BD (Ed), UpToDate, Wellesley, MA, 2000.
4. **J.-F. Dufour**. Non-alcoholic steatohepatitis. Review. OrphaNet. March 2001.
5. **J.-F. Dufour**. Tocopherol and antioxidants in the treatment of the non-alcoholic steatohepatitis. In 'Non-alcoholic and Alcoholic steatohepatitis.' Falk Symposium 121;197-202. Kluwer academic publishers, 2001.
6. D. Semela, **J.-F. Dufour**. Vascular endothelial growth factor signaling. In: **J.-F. Dufour**, P-A Clavien eds. *Signaling pathways in Liver diseases*. Springer 2005.
7. E. Renner, **J.-F. Dufour**. Medical problems after liver transplantation. In: P. Killenberg, P-A. Clavien eds. *Medical care of the liver transplant patient*. Third Ed. Blackwell 2006.
8. **J.-F. Dufour**. Biliary epithelial cells. In: J-P. Benhamou, A. Blei, **J.-F. Dufour**, P. Ginès, S. Friedmann, J. Reichen, J. Rodes, C. Valla, F. Zoulim eds. *Oxford Textbook of Hepatology*. Third Ed. Blackwell 2007.
9. D. Semela, **J.-F. Dufour**. Vascular endothelial growth factor signaling. In: **J.-F. Dufour**, P-A Clavien eds. *Signaling pathways in Liver diseases*. Second Edition. Springer 2009.

10. ML. Balmer, **J-F. Dufour**. Molecular mechanisms of liver cancer metastasis. In: L. Qiao, J. George, eds. Liver Cancer E-book. Bantham Publishers. 2012.
11. C. Hora, **J-F. Dufour**. Primary Hepatocellular Carcinoma. In: P. Monga, ed. Molecular Pathology of Liver Diseases. Springer. 2011.
12. ML. Balmer, **J-F. Dufour**. Biology of Hepatocellular Carcinoma. In: McMasters KM, Vauthey JN, eds. Hepatocellular Carcinoma: Targeted Therapy and Multidisciplinary Care. Springer. 2010.
13. A. Sendensky, **J-F. Dufour**. Physiology of Liver Functions. In: P.Gines, P. Kamath, V. Arroyo. Chronic Liver Failure: Mechanisms and Management. Springer. 2010.
14. A. Buergi, **J-F. Dufour**. Hepatoprotectants against fatty liver disease: antioxidants, ursodeoxycholic acid, and herbal medicines. In: Eds. Geoff Farrell (Canberra, Australia), Arthur McCullough (Cleveland, USA), Christopher Day (Newcastle, UK). Non-alcoholic fatty liver disease. A practical guide. 2013.
15. C. Margini, **J-F. Dufour**. Are the guidelines - AASLD, IASL, EASL, and BSG - of help in the management of patients with NAFLD? In R. Williams and S. D. Taylor-Robinson. Clinical Dilemmas in Non-Alcoholic Fatty Liver Disease. John Wiley & Sons. 2016.

E. Book editor:

1. Signaling Pathways in Liver Diseases. Springer 2005. **J-F. Dufour**, P-A. Clavien, Editors. (35 chapters).
2. Oxford Textbook of Hepatology. Third Ed. Blackwell. JP Benhamou, A. Blei, **J-F Dufour**, P. Ginès, S. Friedmann, J. Reichen, J. Rodes, C. Valla, F. Zoulim Editors. Blackwell 2007.
3. Signaling Pathways in Liver Diseases. Second Edition. Springer 2009. **J-F. Dufour**, P-A. Clavien, Editors. (35 chapters).
4. Signaling Pathways in Liver Diseases. Third Edition. Wiley 2015. **J-F. Dufour**, P-A. Clavien, Editors. (35 chapters).